Literature DB >> 8156682

Age- and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva.

D M Rocke1, M Zasloff, J Peeper, R B Cohen, F S Kaplan.   

Abstract

Using data from a survey of 44 patients who have fibrodysplasia ossificans progressiva, age- and joint-specific risks of new joint involvement were estimated using parametric and nonparametric statistical methods. Regions in which the risk of heterotopic ossification appears to remain constant with age include the neck, spine, shoulders, elbows, and ankles. Regions with apparently increasing risk include the jaw, wrists, hips, and knees. This analysis allows clinicians to estimate the risk of new involvement for any joint at any patient age, as well as the fraction of patients with uninvolved joints at any age. The variation of ossification risk by joint provides a clinically useful guide to the patterns of progression of the disease. Such a guide will help in planning for individual patient needs, as well as anticipating auxiliary social services and rehabilitation programs.

Entities:  

Mesh:

Year:  1994        PMID: 8156682

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  31 in total

1.  Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31.

Authors:  G Feldman; M Li; S Martin; M Urbanek; J A Urtizberea; M Fardeau; M LeMerrer; J M Connor; J Triffitt; R Smith; M Muenke; F S Kaplan; E M Shore
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

Review 2.  Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.

Authors:  Kelly L Wentworth; Umesh Masharani; Edward C Hsiao
Journal:  Br J Clin Pharmacol       Date:  2019-01-06       Impact factor: 4.335

3.  Chin-on-chest deformity in patients with fibrodysplasia ossificans progressiva. A case series.

Authors:  Ryan E Moore; John P Dormans; Denis S Drummond; Eileen M Shore; Frederick S Kaplan; Joshua D Auerbach
Journal:  J Bone Joint Surg Am       Date:  2009-06       Impact factor: 5.284

4.  Fibrodysplasia ossificans progressiva (FOP): watch the great toes!

Authors:  Mutlu Kartal-Kaess; Eileen M Shore; Meiqi Xu; Ludwig Schwering; Markus Uhl; Rudolf Korinthenberg; Charlotte Niemeyer; Frederick S Kaplan; Melchior Lauten
Journal:  Eur J Pediatr       Date:  2010-06-26       Impact factor: 3.183

5.  De novo 617G-A nucleotide mutation in the ACVR1 gene in a Taiwanese patient with fibrodysplasia ossificans progressiva.

Authors:  Gau-Tyan Lin; Hsueh-Wei Chang; Chih-Shan Liu; Peng-Ju Huang; Hsien-Chung Wang; Yuh-Min Cheng
Journal:  J Hum Genet       Date:  2006-11-01       Impact factor: 3.172

6.  Early diagnosis of fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Meiqi Xu; David L Glaser; Felicity Collins; Michael Connor; Joseph Kitterman; David Sillence; Elaine Zackai; Vardit Ravitsky; Michael Zasloff; Arupa Ganguly; Eileen M Shore
Journal:  Pediatrics       Date:  2008-05       Impact factor: 7.124

7.  When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Jay Groppe; Eileen M Shore
Journal:  Drug Discov Today Ther Strateg       Date:  2008

8.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

Authors:  Frederick S Kaplan; Meiqi Xu; Petra Seemann; J Michael Connor; David L Glaser; Liam Carroll; Patricia Delai; Elisabeth Fastnacht-Urban; Stephen J Forman; Gabriele Gillessen-Kaesbach; Julie Hoover-Fong; Bernhard Köster; Richard M Pauli; William Reardon; Syed-Adeel Zaidi; Michael Zasloff; Rolf Morhart; Stefan Mundlos; Jay Groppe; Eileen M Shore
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

Review 9.  Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP).

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Bone       Date:  2008-05-28       Impact factor: 4.398

Review 10.  The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling.

Authors:  Frederick S Kaplan; Robert J Pignolo; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-06       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.